These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 1600834)

  • 21. Extrapancreatic effects of sulfonylurea drugs.
    Kaku K; Inoue Y; Kaneko T
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S105-8. PubMed ID: 8529502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [40 years of using sulfonylurea derivatives for treatment of diabetes].
    Sieradzki J
    Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does insulin preserve beta-cell function in type 2 diabetes?
    Heise T; Sawicki PT
    J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms and Characteristics of Sulfonylureas and Glinides.
    Lv W; Wang X; Xu Q; Lu W
    Curr Top Med Chem; 2020; 20(1):37-56. PubMed ID: 31884929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of NIDDM with insulin agonists or substitutes.
    Galloway JA
    Diabetes Care; 1990 Dec; 13(12):1209-39. PubMed ID: 1980453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glimepiride in daily practice].
    Jasik M
    Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.
    Melander A
    Diabetes; 2004 Dec; 53 Suppl 3():S151-5. PubMed ID: 15561903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
    Prigeon RL; Jacobson RK; Porte D; Kahn SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined insulin-sulfonylurea therapy in treatment of NIDDM.
    Groop LC; Groop PH; Stenman S
    Diabetes Care; 1990 Aug; 13 Suppl 3():47-52. PubMed ID: 2209344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: a preliminary report.
    Takei I; Takayama S; Yamauchi A; Nakamoto S; Kitamura Y; Katsukawa F; Yamazaki H; Saruta T; Inoue S
    Eur J Clin Nutr; 1998 Feb; 52(2):153-4. PubMed ID: 9505163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with insulin and sulfonylureas for type II diabetes.
    Bailey TS; Mezitis NH
    Diabetes Care; 1990 Jun; 13(6):687-95. PubMed ID: 2192852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
    Heine RJ
    Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
    Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabetes mellitus.
    Owens DR
    Am J Med; 1985 Aug; 79(2B):27-32. PubMed ID: 3929599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology of sulfonylureas.
    Melander A
    Metabolism; 1987 Feb; 36(2 Suppl 1):12-6. PubMed ID: 3543616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical use of oral sulfonylureas in the management of non-insulin dependent diabetes mellitus (NIDDM).
    Ponte CD
    W V Med J; 1990 Oct; 86(10):455-8. PubMed ID: 2238629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are sulfonylureas passé?
    Green JB; Feinglos MN
    Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.